In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...